AR108690A1 - ANTIBODIES AGAINST MEMBER 21 OF THE RECEPTOR SUPERFAMILY OF THE TUMOR NECROSIS FACTOR (ANTI-TNFRSF21) AND METHODS OF USE OF THE SAME - Google Patents

ANTIBODIES AGAINST MEMBER 21 OF THE RECEPTOR SUPERFAMILY OF THE TUMOR NECROSIS FACTOR (ANTI-TNFRSF21) AND METHODS OF USE OF THE SAME

Info

Publication number
AR108690A1
AR108690A1 ARP170101187A ARP170101187A AR108690A1 AR 108690 A1 AR108690 A1 AR 108690A1 AR P170101187 A ARP170101187 A AR P170101187A AR P170101187 A ARP170101187 A AR P170101187A AR 108690 A1 AR108690 A1 AR 108690A1
Authority
AR
Argentina
Prior art keywords
tnfrsf21
methods
same
antibodies against
necrosis factor
Prior art date
Application number
ARP170101187A
Other languages
Spanish (es)
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of AR108690A1 publication Critical patent/AR108690A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan anticuerpos anti-TNFRSF21, conjugados de anticuerpo y composiciones farmacéuticas, y métodos para usar dichos anticuerpos anti-TNFRSF21, sus conjugados y composiciones farmacéuticas en el tratamiento de un cáncer.Anti-TNFRSF21 antibodies, antibody conjugates and pharmaceutical compositions, and methods for using said anti-TNFRSF21 antibodies, their conjugates and pharmaceutical compositions in the treatment of cancer are provided.

ARP170101187A 2016-05-06 2017-05-05 ANTIBODIES AGAINST MEMBER 21 OF THE RECEPTOR SUPERFAMILY OF THE TUMOR NECROSIS FACTOR (ANTI-TNFRSF21) AND METHODS OF USE OF THE SAME AR108690A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662332721P 2016-05-06 2016-05-06

Publications (1)

Publication Number Publication Date
AR108690A1 true AR108690A1 (en) 2018-09-19

Family

ID=63667414

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101187A AR108690A1 (en) 2016-05-06 2017-05-05 ANTIBODIES AGAINST MEMBER 21 OF THE RECEPTOR SUPERFAMILY OF THE TUMOR NECROSIS FACTOR (ANTI-TNFRSF21) AND METHODS OF USE OF THE SAME

Country Status (1)

Country Link
AR (1) AR108690A1 (en)

Similar Documents

Publication Publication Date Title
CO2018004315A2 (en) 2-amino-pyrrolo [3,2] pyrimidine conjugates with anti-her-2 antibodies
CO2020016619A2 (en) Bispecific anti-pvrig / anti-tigit antibodies and methods of use
CO2021001912A2 (en) Anti-cd112r compositions and methods
CL2018001722A1 (en) New anti-mfi2 antibodies and methods of use (divisional application 201700506)
CL2018003758A1 (en) Anti-dll3-antibody antibody conjugates and methods of use. (divisional application 201800458)
CY1123977T1 (en) ANTI-PD-1 AND ANTI-LAG3 ANTIBODIES FOR THE TREATMENT OF CANCER
CL2018002878A1 (en) Anti-tim-3 compositions and antibodies.
ECSP17027870A (en) COMPOSITIONS AND METHODS USED TO INCREASE IMMUNE RESPONSE AND IN CANCER THERAPY
CL2017001217A1 (en) Antibody drug conjugates.
CL2016002667A1 (en) Novel anti-rnf43 antibodies and methods for use
ECSP18049762A (en) NEW ANTI-CLAUDIN ANTIBODIES AND THEIR METHODS OF USE
UY37456A (en) IMMUNOGLOBULINAS AND ITS USES
AR104664A1 (en) CONJUGATES OF DRUGS WITH ANTIBODIES AGAINST CADHERINE 6 (ANTI-CDH6)
MX2020004801A (en) Bispecific fusion polypeptides and methods of use thereof.
BR112018010279A2 (en) new anti-emr2 antibodies and methods of use
CL2016001937A1 (en) Functionalized benzopyran compounds and their use
AR120147A1 (en) ANTI-PD-L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
EA201890457A1 (en) COMBINATION ANTIBODY AGAINST THE OX40 AND THE TLR4 MODULATOR AND THEIR APPLICATION
CO2017010692A2 (en) Calicheamycin constructions and their methods of use
BR112018012884A2 (en) new anti-mmp16 antibodies and methods of use
CO2020016151A2 (en) Anti-sez6 Antibody-Drug Conjugates and Methods of Use
BR112018012883A2 (en) new anti-upk1b antibodies and methods of use
CO2018011420A2 (en) Liquid phosphaplatin formulations
AR108690A1 (en) ANTIBODIES AGAINST MEMBER 21 OF THE RECEPTOR SUPERFAMILY OF THE TUMOR NECROSIS FACTOR (ANTI-TNFRSF21) AND METHODS OF USE OF THE SAME
AR110347A1 (en) ANTI-KREMEN2 ANTIBODIES AND METHODS FOR USE

Legal Events

Date Code Title Description
FB Suspension of granting procedure